Tag Archives: Fase II onderzoek

Merus starts Phase I/II clinical trial for MCLA-128

Merus B.V. in Utrecht, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, announced the initiation of a phase I/II clinical study of MCLA-128 for the treatment of solid tumors. MCLA-128 is an ADCC-enhanced, full-length IgG bispecific antibody that simultaneously targets the growth factor receptors HER2 and HER3. “Tumors with intrinsic or acquired resistance to… Read More »